email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

lupinepublishers
lupinepublishers

ISSN: 2637-6628

Online Journal of Neurology and Brain Disorders

Research Article(ISSN: 2637-6628)

A Double-Blind Placebo-Controlled Trial of Acediprol (Valproate Sodium) For Global Severity in Child Autism Spectrum Disorders

Volume 2 - Issue 1

NA Aliyev1* and ZN Aliyev2

  • Author Information Open or Close
    • 1Department of psychiatry and addiction, Azerbaijan State Advanced Training Institute, Azerbaijan
    • 2Department of psychiatry, Azerbaijan Medical University, Azerbaijan

    *Corresponding author: Nadir A Aliyev, Department of psychiatry and addiction, Azerbaijan State Advanced Training Institute, Baku, Azerbaijan

Received: September 22, 2018;   Published: September 28, 2018

DOI: 10.32474/OJNBD.2018.01.000127

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Objectives: The effects of Valproate sodium and placebo on global severity were compared in Child Autism Spectrum Disorders (ASD).

Materials and Methods: Childs with ASDs were enrolled in a 12-week double-blind placebo-controlled Valproate sodium trial. Fifty were randomly assigned to Valproate sodium (n=50) or placebo (n=50). The initial dose of Valproate sodium for children is 15mg/kg, then increases by 5-10mg/kg every week to 20-50mg/kg. Children are given 5% syrup (Sirupus Valproate sodium 5%), 1 ml 50mg. Repetitive behaviors were measured with the Clinical Global Impression (CGI) improvement scale.

Results: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for Valproate sodium than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the Valproate sodium group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: Valproate sodium, 80%; placebo, 12%). Side effects were not observed.

Conclusion: Valproate sodium treatment, compared to placebo, resulted in significantly greater improvement in global severity behaviors, according to CGI rating scale. Valproate sodium appeared to be well tolerated movement score of 2 or less, there were significantly more responders at week 12 in the Valproate sodium group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: Acedipro, 80%; placebo, 12%). Side effects were not observed.

Abstract| Introduction| Materials and Methods| Results | Discussion | Author Disclosure Information | Acknowledgment | References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )